H Nina Kim1,2. 1. Department of Medicine, Division of Allergy & Infectious Diseases, University of Washington, Seattle, WA. 2. Center for AIDS Research, University of Washington, Seattle, WA.
Abstract
PURPOSE OF REVIEW: The burden of chronic hepatitis B (HBV) remains disproportionately high among people living with HIV (PLWH) despite the advent of HBV vaccination and HBV-active antiretroviral therapy (ART). This review summarizes new insights and evolving issues in HIV-HBV coinfection. RECENT FINDINGS: HBV-HIV coinfection is still a leading cause of cirrhosis, hepatocellular carcinoma (HCC) and liver-related mortality more than a decade after the approval of tenofovir. While tenofovir-based ART has been shown to improve rates of HBV virologic suppression and halt fibrosis progression, the long-term benefits on the prevention of end-stage liver disease or HCC in HIV-HBV coinfection have yet to be convincingly demonstrated in PLWH. Missed opportunities for HBV vaccination persist despite evidence of ongoing risk for HBV infection in this population. SUMMARY: Even as we work towards HBV elimination and functional cure, ongoing efforts should focus on optimizing risk stratification as well as uptake of HBV-active antiviral therapy and HBV immunization in this priority population.
PURPOSE OF REVIEW: The burden of chronic hepatitis B (HBV) remains disproportionately high among people living with HIV (PLWH) despite the advent of HBV vaccination and HBV-active antiretroviral therapy (ART). This review summarizes new insights and evolving issues in HIV-HBV coinfection. RECENT FINDINGS: HBV-HIV coinfection is still a leading cause of cirrhosis, hepatocellular carcinoma (HCC) and liver-related mortality more than a decade after the approval of tenofovir. While tenofovir-based ART has been shown to improve rates of HBV virologic suppression and halt fibrosis progression, the long-term benefits on the prevention of end-stage liver disease or HCC in HIV-HBV coinfection have yet to be convincingly demonstrated in PLWH. Missed opportunities for HBV vaccination persist despite evidence of ongoing risk for HBV infection in this population. SUMMARY: Even as we work towards HBV elimination and functional cure, ongoing efforts should focus on optimizing risk stratification as well as uptake of HBV-active antiviral therapy and HBV immunization in this priority population.
Entities:
Keywords:
Coinfection; Hepatitis B; Human immune deficiency virus (HIV)
Authors: J F Colin; D Cazals-Hatem; M A Loriot; M Martinot-Peignoux; B N Pham; A Auperin; C Degott; J P Benhamou; S Erlinger; D Valla; P Marcellin Journal: Hepatology Date: 1999-04 Impact factor: 17.425
Authors: Oluwaseun Falade-Nwulia; Eric C Seaberg; Charles R Rinaldo; Sheila Badri; Mallory Witt; Chloe L Thio Journal: Clin Infect Dis Date: 2012-04-20 Impact factor: 9.079
Authors: Mohaned Shilaih; Alex Marzel; Alexandra U Scherrer; Dominique L Braun; Helen Kovari; Mathieu Rougemont; Katharine Darling; Manuel Battegay; Matthias Hoffmann; Enos Bernasconi; Cedric Hirzel; Huldrych F Günthard; Roger D Kouyos Journal: J Infect Dis Date: 2016-05-18 Impact factor: 5.226
Authors: S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao Journal: Hepatol Int Date: 2015-11-13 Impact factor: 6.047
Authors: Alicia C Thornton; Sophie Jose; Sanjay Bhagani; David Chadwick; David Dunn; Richard Gilson; Janice Main; Mark Nelson; Alison Rodger; Chris Taylor; Elaney Youssef; Clifford Leen; Mark Gompels; Stephen Kegg; Achim Schwenk; Caroline Sabin Journal: AIDS Date: 2017-11-28 Impact factor: 4.177